News

CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial

15th August 2024

CV6 Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168   Belfast, UK, 15 August 2024 – CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing novel, first-in-class, small molecules targeting Uracil-DNA […]

Read More

CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

13th May 2024

Belfast, UK, 10 May 2024 – CV6 Therapeutics (‘CV6’) is a clinical-stage drug development company targeting Uracil-DNA biology to transform the treatment of cancer and inflammatory diseases. CV6 will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on […]

Read More

CV6 Therapeutics to Attend JP Morgan Week

5th January 2024

CV6 Therapeutics Inc., CEO and Founder, Dr Robert Ladner will be attending JP Morgan Week, to be held on the 8th-12th January at the Marriott Marquis in San Francisco, California, USA. CV6 Therapeutics is a drug development company focussed on developing value-based, first-in-class medications that are scalable to address global unmet medical needs. JP Morgan […]

Read More

CV6 Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial

14th December 2023

Belfast, UK, 14 December 2023 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has received approval from the UK’s medicines regulator, the MHRA, for the company’s first-in-human Phase 1a clinical trial of its lead oncology therapeutic, CV6-168, in patients with colorectal and […]

Read More

CV6 CEO Co-authors Study on Cancer Care in Ireland

25th October 2023

All-Island Study Highlights the Cancer Legacy of the Good Friday Agreement New all-island research led by Queen’s University Belfast highlights the health and economic impact of the Good Friday Agreement on cancer across the island of Ireland in the last 25 years. The work, involving researchers from Northern Ireland, Ireland, the UK and the U.S. […]

Read More

CV6 CEO Presents at ‘Agreement 25: Cancer Knows no Borders’

19th April 2023

The focus of the world was on Belfast as global political leader’s past, and present arrived in Belfast to mark the 25th anniversary of the Belfast/Good Friday Agreement. The three-day conference (17-19th April) hosted by Queens University Belfast provided a unique opportunity for reflection on the Agreement’s impact on Northern Ireland and its place on the […]

Read More

CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial

2nd November 2022

Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work. Investors participating in the financing […]

Read More

CV6 Therapeutics Featured in the NI Edition of the 12 Clusters of Tech

5th January 2021

Belfast, UK. 5th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases,  have been featured in the November 2020 special report on the ‘12 Clusters of Tech’, a national campaign to champion leading clusters of UK technology led by the UK Tech Cluster […]

Read More

CV6 Therapeutics Inc Recognised as a Platinum Level Innovator

4th January 2021

Belfast, UK. 4th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that they have been recognised as a Platinum Level Innovator by Innovate Northern Ireland on behalf of the Department of the Economy for Northern Ireland. The award was based […]

Read More

CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event

15th March 2019

Belfast, UK. 15th March, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that CEO and Founder Dr Robert Ladner has been invited to participate in the Europe CEO networking forum in Vienna, Austria on the 24th of March, 2019. Europe CEO is […]

Read More